Editorial: The status of pulmonary arterial hypertension in 2008

Circulation

Volumn 117, Issue 23, 2008, Pages 2966-2968

  Farber, Harrison W ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Editorials; Hypertension; Pulmonary; Pulmonary heart disease

Indexed keywords

AMBRISENTAN; BERAPROST; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CALCIUM CHANNEL BLOCKING AGENT; PROSTANOID; ANTIHYPERTENSIVE AGENT; PHENYLPROPIONIC ACID DERIVATIVE; PROSTACYCLIN; PYRIDAZINE DERIVATIVE; VASODILATOR AGENT;

CARDIAC PATIENT; CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; FAMILIAL DISEASE; FUNCTIONAL STATUS; GENE MUTATION; HEALTH STATUS; HEART RIGHT VENTRICLE FUNCTION; HUMAN; IDIOPATHIC DISEASE; KINESIOTHERAPY; MEAN ARTERIAL PRESSURE; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; WALKING; NOTE; RANDOMIZED CONTROLLED TRIAL;

ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; PHENYLPROPIONATES; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASODILATOR AGENTS;

EID: 46449092530     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.782979     Document Type: Editorial

References (12)

1. Galiè N. Olschewski H. Oudiz RJ. Torres F. Frost A. Ghofrani HA. Badesch DB. McGoon MD. McLaughlin VV. Roecker EB. Gerber MJ. Dufton C. Wiens BL. Rubin LJ. for the Ambrisentan in Pulmonary Arterial Hypertension. Randomized. Double-blind. Placebo-Controlled. Multicenter. Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension. Randomized. Double-Blind. Placebo-Controlled. Multicenter. Efficacy (ARIES) Study 1 and 2. Circulation. 2008;117: 3010-3019.
2. Macchia A. Marchioli R. Marfisi RM. Scarano M. Levantisi G. Tavazzi L. Tognoni G. A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology. Am Ht J. 2007;153:1037-1047.
3. Barst RJ. Rubin LJ. Long WA. McGoon MD. Rich S. Badesch DB. Groves BM. Tapson VF. Bourge RC. Brundage BH. Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension. N Engl J Med. 1996;334: 296-301.
4. Mereles D. Ehlken N. Kreuscher S. Ghofrani S. Hoeper MM. Halank M. Meyer FJ. Karger G. Buss J. Juenger J. Holzapfel N. Opitz C. Winkler J. Herth FF. Wilkens H. Katus HA. Olschewski H. Griinig E. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006; 14:1482-1489.
5. Farber HW. Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655-1665.
6. Roberts K. Preston I. Hill NS. Pulmonary hypertension trials. Current end points are flawed. but what are the alternatives? Chest. 2006;130: 934-936.
7. Rich S. The value of approved therapies for pulmonary arterial hypertension. Am Ht J. 2007;153:889-890.
8. Barst. RJ. McGoon M. McLaughlin V. Tapson V. Rich S. Rubin L. Wasserman K. Oudiz R. Shapiro S. Robbins IM. Channick R. Badesch D. Rayburn BK. Flinchbaugh R. Sigman J. Arneson C. Jeffs R. Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:2119 -2125.
9. McLaughlin VV. Presberg KW. Doyle RL. Abman SH. McCrory DC. Fortin T. Ahearn G. Prognosis of pulmonary arterial hypertension. Chest. 2004;126:78S-92S.
10. Sitbon O. Humbert M. Jais X. Ioos V. Hamid AM. Provencher S. Garcia G. Parent F. Herve P. Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111:3105-3111.
11. Newman JH. Phillips JA 3rd. Loyd JE. Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies. Ann Intern Med. 2008;148:278-283.
12. Arcasoy SM. Christie JD. Ferrari VA. Sutton MS. Zisman DA. Blu-menthal NP. Pochettino A. Kotloff RM. Am J Respir Crit Care Med. 2003;167:735-740.